David Hung

David Hung is a declared insider at 5 companies (board member); the most frequent names are Medivation, Inc., Acer Therapeutics Inc. and Novocure Ltd. In total, 102 filings cover trades dated from 5 April 2005 to 16 June 2025.

In open-market terms, that means 4 purchases worth €10.9M on one side and 65 sales worth €58.8M on the other. The net balance comes to €47.9M on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 18 share grants and 5 option exercises. In 2025 alone, the filings show 3 purchases and 1 sale.

In size, the median ticket on the buying side is €611k. Clusters matter here: 4 out of 4 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The record was last updated on 18 June 2025 with an open-market purchase (€774k) in Nuvation Bio Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.